rhGALC Purification via Multimodal Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for purifying recombinant human Galactocerebroside β-Galactosidase (rhGALC) are complex, result in low recoveries, and produce mixtures of full-length and processed forms, making them unsuitable for large-scale enzyme replacement therapy due to the enzyme's extreme hydrophobicity and low abundance.
Innovation Solution
A three-phase chromatographic purification process involving capture, intermediate, and polishing steps using specific resins like Capto™ Blue, Capto™ Adhere, and Toyopearl Ether, along with optional virus inactivation/removal steps, to produce a homogenous, high-purity rhGALC product suitable for human use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If previous purification methods are used for rhGALC, then the enzyme can be partially purified from natural specimens, but the recovery is extremely low and the product is a mixture of full-length and processed forms
Solution Approach 1:
The purification process is divided into three sequential chromatographic steps (capture, intermediate, and polishing), each targeting specific impurities. This segmentation allows progressive purification while maintaining high recovery at each stage, ultimately achieving >95% pure full-length rhGALC with high yield
Solution Approach 2:
The patent employs multimodal chromatographic resins that utilize multiple binding mechanisms (hydrophobic, electrostatic, hydrogen bonding) simultaneously. By adjusting buffer conditions (pH, ionic strength, organic modifiers) across the three steps, the process optimizes binding and elution parameters to maintain enzyme stability and achieve high purity and recovery
2Manufacturing precision
If complex purification protocols are used to address hydrophobicity, then some purification is achieved, but the methods become complicated and unsuitable for large-scale production
Solution Approach 1:
The patent uses multimodal chromatographic resins that perform multiple purification functions simultaneously (hydrophobic interaction, ion exchange, hydrogen bonding) in a single step. This multi-functionality reduces the number of separate purification steps needed, simplifying the overall process while maintaining high effectiveness for large-scale production
Solution Approach 2:
The patent introduces specific buffer components (organic modifiers like ethanol or isopropanol, detergents like Tween 20 or Triton X-100) as intermediaries to mediate the interaction between the hydrophobic rhGALC enzyme and the chromatographic resins. These intermediaries reduce direct hydrophobic aggregation and facilitate smooth binding and elution, simplifying the purification process
3Manufacturing precision
If traditional chromatographic methods are used, then purification can be achieved, but the extreme hydrophobicity of GALC causes low abundance and poor purification results
Solution Approach 1:
The patent employs composite chromatographic resins that combine multiple functional groups (hydrophobic, ionic, hydrogen-bonding capabilities) within a single matrix. This composite structure allows simultaneous exploitation of multiple molecular interactions, enhancing the capture and purification of low-abundance hydrophobic rhGALC while maintaining high purification quality
Solution Approach 2:
The patent uses buffer additives (organic modifiers and detergents) as intermediaries that temporarily associate with the hydrophobic rhGALC, reducing its extreme hydrophobicity and improving solubility and abundance during the purification process, thereby enabling effective chromatographic separation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves a high yield of homogenous, high-purity rhGALC, suitable for enzyme replacement therapy, effectively addressing the challenges of previous methods by stabilizing the enzyme and removing contaminants, thereby improving the product's quality and purity.
Implementation Method 1
a capture step in which said rhGALC is purified on a first multimodal chromatographic resin which binds through at least hydrophobic and electrostatic interactions
Implementation Method 2
a capture step in which said rhGALC is purified on a first multimodal chromatographic resin which binds through at least hydrophobic and electrostatic interactions
Implementation Method 3
An intermediate step in which said rhGALC is purified on a second multimodal chromatographic resin comprising an anionic and hydrophobic ligand
Implementation Method 4
An intermediate step in which said rhGALC is purified on a second multimodal chromatographic resin comprising an anionic and hydrophobic ligand
Implementation Method 5
a polishing step in which said rhGALC is purified on a chromatographic resin which is selected from the group consisting of a multimodal chromatography resin, an anion exchange resin and a hydrophobic interaction chromatography (HIC) resin
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a process for purifying recombinant human Galactocerebroside β-Galactosidase (rhGALC) from a cell culture, wherein a fraction of said cell culture comprising rhGALC is subjected to chromatography on three distinct resins.